These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31104525)

  • 1. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
    Baljevic M; Orlowski RZ
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):459-473. PubMed ID: 31104525
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
    Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD
    Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The power of proteasome inhibition in multiple myeloma.
    Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
    Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixazomib for the treatment of multiple myeloma.
    Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S
    Expert Opin Pharmacother; 2018 Dec; 19(17):1949-1968. PubMed ID: 30422008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib for the treatment of non-Hodgkin's lymphoma.
    Bose P; Batalo MS; Holkova B; Grant S
    Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
    Bai Y; Su X
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
    Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
    Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome and proteasome inhibitors in multiple myeloma.
    Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.